We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Releases Clinical Hold on Rocket Pharma’s Gene Therapy for Danon Disease
FDA Releases Clinical Hold on Rocket Pharma’s Gene Therapy for Danon Disease
The FDA has lifted its clinical hold on Rocket Pharmaceuticals’ investigational gene therapy for Danon disease, an ultra-rare genetic disorder that can lead to heart failure in children and young adults.